Bruton's Tyrosine Kinase drug trial offers cancer hope

Professor Simon Rule Consultant haematologist Professor Simon Rule is leading the study

Related Stories

A cancer drug which clinicians hope can prolong the lives of terminally ill cancer patients has been trialled for the first time, a hospital trust says.

The trial, in Plymouth, is testing drugs called Bruton's Tyrosine Kinase (BTK) inhibitors to target the severest forms of leukaemia and lymphoma.

Prof Simon Rule, who led the study into the new class of drug, said it meant a "transformation" in treatment.

The trial began in the city in 2012 and has since extended worldwide.

The National Institute for Health and Clinical Excellence (NICE), which guides NHS trusts on treatments, declined to comment.

BTK inhibiting drugs:

  • Oral tablets taken once a day
  • Very few side effects
  • Potential to replace chemotherapy
  • Switch off all symptoms of the disease
  • Broad range of patients suitable, including older, frail patients and those with existing illness
  • Improve life expectancy and quality of life

Source: Plymouth Hospitals NHS Trust

Dr Kat Arney, Cancer Research UK's science communications manager, said: "This new study is very small and the results haven't yet been fully published in the scientific literature, so it's too early to say how effective this specific drug might be.

"Other drugs that block Bruton's Tyrosine Kinase are already showing promise in clinical trials and could be useful in the future for treating people with leukaemia and lymphoma."

Prof Rule, a consultant haematologist at Plymouth Hospitals NHS Trust, has been involved at the trial at Derriford Hospital and also carried out research at Plymouth University.

"The astonishing thing about these drugs is that they have virtually no side effects, which is unprecedented from my experience. In some patients the effects are immediate," he said.

"Patients with lots of symptoms, particularly those with lymphoma, will feel better the next day after taking the medication," he added.

Prof Rule said the tablet-based drugs, which are produced in Japan, targeted the signalling pathways of a cell.

"For the abnormal cells to survive they have to constantly tell themselves to live. If you interrupt the pathway, they die," he explained.

He added that normal cells were not dependent on this and it was specific to the cancerous cells.

'Fighting fit'
Cancer patient David Hodge David Hodge said he had been given only months to live after his immune system began to fail

Plymouth Hospitals NHS Trust said the first four patients in the world to receive this drug were treated in the city as part of the trial, which started in September 2012.

Since then, more than 30 patients worldwide have received treatment, it added.

Prof Rule said the response rate to the drug was close to 100%.

Chronic lymphocytic leukaemia (CLL)

  • CLL usually develops very slowly and many people do not need treatment for months or years
  • With CLL, the body makes too many white blood cells called lymphocytes
  • Over time, these abnormal lymphocytes build up in the lymphatic system and may cause large, swollen lymph nodes

Source: Macmillan Cancer Support

David Hodge, 74, from Plymouth, has suffered chronic lymphocytic leukaemia for 17 years.

Prior to starting the trial in September 2012, Mr Hodge had been given only months to live. His immune system was not functioning and becoming resistant to all other treatments.

Mr Hodge, who takes the medication every morning, said: "I'm fighting fit. I've had no problems, no side effects, nothing.

"I think with any new trial or drug, or with chemotherapy, there's a little bit of trepidation.

"I just felt, even if it proves at this moment, to be of little use to me; I trust that with fine tuning it will prove to be significant to those taking the drug later on."

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

BBC Devon

Weather

Plymouth

22 °C 17 °C

Features

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.